Chelation Therapy for Heart Disease: The TACT Trial

Atherosclerotic plaques accumulate transition metals — particularly lead, cadmium, and iron — from lifelong low-level environmental exposure. These metals catalyze free radical formation through Fenton chemistry, potentially accelerating plaque inflammation, endothelial dysfunction, and plaque instability [1].

EDTA chelation could theoretically reduce this metal-catalyzed oxidative stress by removing catalytic metals from the vasculature. The infusion solutions used in TACT also contained high-dose vitamins and minerals, adding a potential (confounding) antioxidant component.

This mechanism is biologically plausible. Plausibility, however, is not evidence.

The TACT Trial: Design and Results

Study design

TACT (Trial to Assess Chelation Therapy) was funded by NCCIH and NHLBI. It enrolled 1,708 patients aged 50+ who had experienced a myocardial infarction at least 6 weeks prior. The trial was double-blind, placebo-controlled, and randomized [2].

• Treatment arm: 40 IV infusions of a solution containing 3g disodium EDTA, 7g ascorbic acid, B vitamins, electrolytes, and other components
• Placebo arm: Normal saline with equivalent volume and appearance
• Duration: Infusions weekly for 30 weeks, then bimonthly for maintenance
• Primary endpoint: Composite of death, MI, stroke, coronary revascularization, or hospitalization for angina

Overall results

The chelation group showed an 18% relative risk reduction in the primary composite endpoint (HR 0.82, 95% CI 0.69–0.99, p = 0.035). The absolute risk reduction was approximately 4.6 percentage points over a median 55 months of follow-up [2].

This reached statistical significance — but barely. The confidence interval barely excluded 1.0, and the p-value was just under the threshold.

The diabetes subgroup

Among the 633 patients with diabetes (37% of the total), results were much more dramatic:

• 39% reduction in the primary endpoint (HR 0.61, 95% CI 0.45–0.83, p = 0.002)
• 43% reduction in total mortality (HR 0.57, 95% CI 0.36–0.88)

These are large effect sizes with strong statistical significance. However, this was a subgroup analysis — not the primary endpoint. Subgroup analyses, even pre-specified ones, are hypothesis-generating, not confirmatory [3].

Non-diabetic patients

Among non-diabetic participants, chelation showed no significant benefit (HR 0.96, 95% CI 0.77–1.20). The overall trial result was essentially driven entirely by the diabetic subgroup.

Why TACT Hasn’t Changed Cardiology Practice

Several factors explain why the AHA, ACC, and ESC have not adopted chelation into cardiovascular guidelines:

1. Borderline overall significance. A p-value of 0.035 in a single trial is not the strength of evidence required to recommend a novel therapy with significant cost and time burden.

2. Subgroup-driven results. When the overall effect depends entirely on one subgroup, the evidence is weaker than headlines suggest. The non-diabetic majority showed nothing.

3. Complex intervention. The infusion contained EDTA plus vitamins plus minerals. Attributing benefit specifically to chelation (vs. high-dose ascorbic acid, etc.) is not possible from the trial design.

4. Potential unblinding concerns. Some critics noted that the taste and infusion sensation of EDTA may have differed from saline, potentially compromising blinding. The investigators dispute this, but it’s a legitimate concern in a trial with borderline results.

5. Single trial. One trial, regardless of quality, typically does not change practice for a major disease category. Replication is needed [4].

TACT2: The Follow-Up

TACT2 was designed to specifically test chelation in post-MI patients with diabetes — the subgroup that showed dramatic benefit in TACT1. It was also NIH-funded and double-blind.

As of early 2026, TACT2 enrollment is complete and results have been presented at scientific meetings. The trial did not replicate the dramatic diabetes-subgroup results from TACT1 with the same effect magnitude, though detailed published analysis continues. This has tempered enthusiasm somewhat, though proponents argue study population differences and COVID-era enrollment challenges may have affected outcomes [5].

The bottom line: TACT2 has not provided the decisive confirmation that chelation advocates hoped for.

What Alternative/Integrative Clinics Offer

Many naturopathic and integrative medicine clinics offer IV chelation for cardiovascular purposes, typically marketing it as:

• “Plaque removal” or “arterial cleaning”
• A way to avoid bypass surgery or stenting
• Prevention for people with cardiovascular risk factors

The reality check

• TACT studied post-MI patients on standard medical therapy. It did not study prevention in healthy people or people with risk factors alone.
• Chelation does not physically remove atherosclerotic plaques. The proposed mechanism is reduction of metal-catalyzed oxidative stress — not “cleaning arteries.”
• At $100–$150 per infusion × 40 infusions, the cost is $4,000–$6,000+ and is almost never covered by insurance for cardiovascular indications.
• This investment of time and money has an opportunity cost — patients choosing chelation over established therapies (statins, antihypertensives, lifestyle modification) may fare worse.

The Honest Bottom Line

The TACT trial is legitimate science that produced an interesting signal, particularly for diabetic post-MI patients. It deserved a follow-up trial, which it got.

But “interesting signal in one trial” is not “proven therapy.” The evidence does not support chelation as a routine cardiovascular treatment, as a substitute for standard cardiac medications, or as a preventive intervention for heart disease.

If you’re a diabetic post-MI patient curious about chelation, having a conversation with a cardiologist who knows the TACT data is reasonable. Signing up for a $5,000 infusion series at a wellness clinic based on marketing claims about “arterial detox” is not.

---

Frequently Asked Questions

Did the TACT trial prove chelation therapy works for heart disease?

TACT showed a statistically significant reduction in cardiovascular events, but this has not been accepted as proof of efficacy by major cardiology societies due to methodological concerns about blinding and mechanism. It is viewed as hypothesis-generating—justifying further research—not as definitive evidence for clinical practice change.

Why is chelation controversial for heart disease?

The main concerns are: imperfect blinding (participants may have noticed differences between active chelation and placebo), lack of a plausible mechanism for the cardiovascular benefit (EDTA removes heavy metals, but the connection to atherosclerosis is not well established), and the unexpectedly large effect size compared to other interventions.

What is TACT2 and when will results be available?

TACT2 is a follow-up trial specifically in diabetic patients who have had a prior heart attack—the subgroup that showed the largest TACT benefit. Enrollment has been underway; results are expected to help determine whether the original TACT findings are replicable and specific to this population.

Should I get chelation therapy for heart disease?

Not based on current evidence and guidelines. Chelation therapy for cardiovascular disease is not approved by the FDA for this indication and is not endorsed by the American Heart Association or American College of Cardiology. Discuss any interest in chelation with a cardiologist familiar with the TACT literature.

References

[1] Lamas GA, Ergui I. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? Expert Rev Cardiovasc Ther. 2016;14(8):927-938.

[2] Lamas GA, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241-1250.

[3] Escolar E, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014;7(1):15-24.

[4] Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA. 2013;309(12):1293-1294.

[5] Lamas GA, et al. TACT2: Trial to Assess Chelation Therapy 2. ClinicalTrials.gov identifier NCT02733185.

Related Articles

• Chelation Therapy Risks, Side Effects, and Safety: What Can Go Wrong
• Chelation Therapy for Heavy Metal Poisoning: What It Treats, How It Works, and When Its Necessary
• Chelation Therapy in 2026: Legitimate Uses, Supplement Hype, and What the Evidence Actually Shows
• Best Vitamin D3 + K2 Supplements for Bone and Heart Health in 2026: What the Evidence Actually Shows
• LED Therapy for Acne Scars: What It Can and Cannot Do

Sources

• EDTA Chelation Reappraisal: Review of Clinical Trials and Risk/Benefit (2012)
• Chelation in Metal Intoxication: Review of Agents and Strategies (2010)
• Role of Chelation in Treatment of Other Metal Poisonings (2013)
• Bovine Colostrum and Immune Effects: Review (2021)
• Bovine Colostrum on Immunity: Review (2024)